<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839643</url>
  </required_header>
  <id_info>
    <org_study_id>AVM-01001</org_study_id>
    <nct_id>NCT01839643</nct_id>
  </id_info>
  <brief_title>Assessment of a Vaginal Ring With Meloxicam on Ovarian Cycle in Fertile Women</brief_title>
  <official_title>Phase 1 Study of Assessment of Local Absorption of a Non-steroidal Antiinflammatory Drug (NSAID), Inhibitor of Cyclooxygenase 2 (COX-2) Meloxicam, Through a Vaginal Ring and Its Effect on Ovarian Cycle in Fertile Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Andromaco S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Chileno de Medicina Reproductiva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Andromaco S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators propose to assess if a non-hormonal agent is absorbed by a
      local route (vaginal) and to observe the effect on follicular development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each volunteer will participate for 3 menstrual cycles, beginning with one menstrual control
      cycle without treatment, following by one menstrual cycle with meloxicam ring administration,
      and finishing with another control menstrual cycle.

      Meloxicam will be administered in the second menstrual cycle via a vaginal ring in two doses
      of 2.4 g or 3.0 g/ring. The safety of the vaginal ring and the absorption of meloxicam will
      be assessed. Also the effect on follicular development and if it maintains ovarian cyclicity,
      as shown in a recent study with oral administration, will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2013</start_date>
  <completion_date type="Actual">June 6, 2013</completion_date>
  <primary_completion_date type="Actual">May 7, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with follicular rupture delay</measure>
    <time_frame>Participants will be followed for the duration of one menstrual cycle, an expected average of 28 days</time_frame>
    <description>Evaluate effective dose of maximum local safety that causes a greater proportion of follicular rupture delays when it is administered continuously, starting on the day 5 +/- 1 of the cycle until next menses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of meloxicam via vaginal route: AUC</measure>
    <time_frame>An expected average of 28 days</time_frame>
    <description>The AUC of meloxicam serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding patterns with meloxicam vaginal ring</measure>
    <time_frame>one menstrual cycle</time_frame>
    <description>Women will complete a menstrual diary during their participation to evaluate the effects of treatment on the menstrual pattern.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of meloxicam via vaginal route: Tmax</measure>
    <time_frame>An expected average of 28 days</time_frame>
    <description>Tmax of meloxicam serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of meloxicam via vaginal route: Cmax</measure>
    <time_frame>An expected average of 28 days</time_frame>
    <description>Cmax of meloxicam serum levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Contraception</condition>
  <condition>Bleeding Pattern</condition>
  <arm_group>
    <arm_group_label>2.4 g Meloxicam Vaginal Ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous wearing during one menstrual cycle (6 participants)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 g Meloxicam Vaginal Ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous wearing during one menstrual cycle (6 participants)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 2.4 g</intervention_name>
    <description>2.4 g in Vaginal Ring</description>
    <arm_group_label>2.4 g Meloxicam Vaginal Ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 3.0 g</intervention_name>
    <description>3.0 g in Vaginal Ring</description>
    <arm_group_label>3.0 g Meloxicam Vaginal Ring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous (or history of) proven fertility

          -  Regular menstrual cycle

          -  Surgically sterile

          -  Without breastfeeding

          -  Haemoglobin at least 11g/dL

          -  Willing to participate in the study

        Exclusion Criteria:

          -  Allergy to meloxicam or other NSAID

          -  Allergy to silicone polymer

          -  Vaginal discharge non diagnosticated

          -  History of shock toxic syndrome

          -  History of : gastrointestinal, bleeding, renal, liver, heart, brain,clot, endocrine or
             pulmonary disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grünenthal Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Grünenthal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Chileno de Medicina Reproductiva (ICMER)</name>
      <address>
        <city>Santiago</city>
        <zip>8320165</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <link>
    <url>http://www.icmer.org</url>
    <description>Link to clinical site</description>
  </link>
  <reference>
    <citation>Jesam C, Salvatierra AM, Schwartz JL, Croxatto HB. Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. Hum Reprod. 2010 Feb;25(2):368-73. doi: 10.1093/humrep/dep392. Epub 2009 Nov 19.</citation>
    <PMID>19933235</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

